NeoGenomics (NEO) Q1 2025 Earnings Call April 29, 2025 01:46 PM ET Speaker0 Greetings, and welcome to the NeoGenomics First Quarter twenty twenty five Conference Call. At this time, all participants are on a listen only mode, and a question and answer session will follow the formal presentation. Please note this conference is being recorded. I will now turn the conference over to your host, Kendra Sweeney, VP of Investor Relations. Ma'am, you may begin. Speaker1 Thank you, Ellie. Good morning, everyone, and ...

1Q 2025 Financial Results Nasdaq: NEO 1 April 29, 2025 Safe Harbor Statements This presentation has been prepared by NeoGenomics, Inc. ("we," "us," "our," "NeoGenomics" or the "Company") and is made for informational purposes only and does not constitute an offer to sell or a solicitation of an offer to buy securities, nor shall there be any sale of any securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securit ...

Group 1 - NeoGenomics reported break-even quarterly earnings per share, surprising the market as the consensus estimate was a loss of $0.02, marking a 100% earnings surprise [1] - The company posted revenues of $168.04 million for the quarter ended March 2025, which was 1.66% below the Zacks Consensus Estimate, but an increase from $156.24 million year-over-year [2] - Over the last four quarters, NeoGenomics has surpassed consensus EPS estimates four times and topped revenue estimates twice [2] Group 2 - NeoGenomics shares have declined approximately 39.5% since the beginning of the year, contrasting with the S&P 500's decline of 6% [3] - The company's earnings outlook is crucial for investors, as it includes current consensus earnings expectations for upcoming quarters [4] - The current consensus EPS estimate for the next quarter is $0.04 on revenues of $183.07 million, and for the current fiscal year, it is $0.16 on revenues of $738.2 million [7] Group 3 - The Medical - Biomedical and Genetics industry, to which NeoGenomics belongs, is currently ranked in the top 31% of over 250 Zacks industries, indicating a favorable outlook [8] - Empirical research shows a strong correlation between near-term stock movements and trends in earnings estimate revisions, which can impact NeoGenomics' stock performance [5][6]

Fort Myers, Florida (April 29, 2025) - NeoGenomics, Inc. (NASDAQ: NEO) (the "Company"), a leading provider of oncology diagnostic solutions that enable precision medicine, today announced its first-quarter results for the period ended March 31, 2025. Exhibit 99.1 NeoGenomics Reports First Quarter 2025 Results Consolidated Revenue Increased 8% to $168 million First Quarter 2025 Highlights As Compared To First Quarter 2024 "Our business is off to a solid start in 2025 with our team delivering a record number ...

TORONTO, April 25, 2025 (GLOBE NEWSWIRE) -- NEO Battery Materials Ltd. (“NEO” or the “Company”) (TSXV: NBM) (OTC: NBMFF), a low-cost silicon anode materials developer that enables longer-running, rapid-charging lithium-ion batteries, as part of the Battery Board Transition Initiative, is highly pleased to announce the appointment of Mr. Kenneth Hoffman, CFA, CIM, to its Board of Directors, effective immediately. Mr. Hoffman is an internationally distinguished expert in battery materials with over 30 years o ...

About SBC Medical SBC Medical, headquartered in Irvine, California and Tokyo, Japan, owns and provides management services and products to cosmetic treatment centers. The Company is primarily focused on providing comprehensive management services to franchisee clinics, including but not limited to advertising and marketing needs across various platforms (such as social media networks), staff management (such as recruitment and training), booking reservations for franchisee clinic customers, assistance with ...

TORONTO, March 18, 2025 (GLOBE NEWSWIRE) -- NBMSiDE® P-300N: Advanced Prototype for Mass-Producibility Testing with Highest Capacity Retention Achieved to Date Average Coulombic Efficiency of Over 99.8% with High Initial Capacity While Maintaining Low-Cost ProductionTwo Variations of P-300N Launched for Different Industry Requirements Undergoing Long-Term Battery Performance Testing with P-300N & High Capacity Retention Realized Over 300 CyclesMass-Producibility Testing Conducted with P-300N Will Produce N ...

Today, I want to take a look at NeoGenomics (NASDAQ: NEO ). We will review their Q4'24 results and assess their position in the market, understanding how much head-room the company has for growth. After that, we will take a quick lookI am a value dividend investor with an eye for heavy long term compounding. Whenever I see a company that is heavily undervalued with large upside, I always jump in to take my share of the riches. I have been investing since I can remember, specialising in long term growth divi ...

Revenue and Financial Performance - Revenue increased by 11.6% compared to 2023[248] - Consolidated revenue for the year ended December 31, 2024, was $660,566,000, representing an increase of 11.6% compared to $591,643,000 in 2023[273] - Net revenue for 2024 reached $660,566, an increase of 11.7% from $591,643 in 2023[329] - Gross profit for 2024 was $290,100,000, with a gross profit margin of 43.9%, up from 41.3% in 2023[275] - The net loss for 2024 was $78,726, a reduction from the net loss of $87,968 in 2023, indicating improved financial performance[329] - Adjusted EBITDA improved by $36.1 million to positive $39.6 million compared to 2023[248] - Adjusted EBITDA for 2024 was $39,608,000, significantly higher than $3,486,000 in 2023, reflecting improved operational performance[296] Operational Efficiency and Cost Management - Cost of revenue for 2024 was $370,466,000, which is 56.1% of revenue, down from 58.7% in 2023, indicating improved efficiency[275] - General and administrative expenses increased to $259,737,000 in 2024, accounting for 39.3% of revenue, down from 41.1% in 2023[279] - Research and development expenses rose to $31,159,000 in 2024, representing 4.7% of revenue, compared to 4.6% in 2023[281] - Sales and marketing expenses increased to $84,652,000 in 2024, which is 12.8% of revenue, up from 12.0% in 2023[283] - Restructuring charges decreased to $6,658,000 in 2024, representing 1.0% of revenue, down from 2.0% in 2023[286] - The company is committed to improving operational efficiency and achieving positive cash flow from operations[249] Cash Flow and Liquidity - For the year ended December 31, 2024, cash provided by operating activities was $7.0 million, a $9.0 million increase compared to cash used of $2.0 million in 2023, primarily driven by an improvement in gross profit of $45.5 million[299] - Cash provided by investing activities was $12.9 million for the year ended December 31, 2024, a significant decrease from $76.7 million in 2023, due to a $58.3 million decrease in sales and maturities of marketable securities[300] - As of December 31, 2024, the company had $367.0 million in cash and cash equivalents, along with $19.8 million in marketable securities, sufficient to support operational liquidity needs for at least the next 12 months[302] - The net change in cash and cash equivalents for the year ended December 31, 2024, was $24.5 million, compared to a net change of $79.3 million in 2023[298] - The company experienced a $16.1 million reduction in cash used by operating activities year-over-year, attributed to improved operating results[299] Investments and Future Plans - The company plans to invest in information technology and automation to drive down testing costs[247] - The company anticipates capital expenditures for the year ended December 31, 2025, to be in the range of $30 million to $35 million, following approximately $41.1 million spent on capital equipment, software, and leasehold improvements in 2024[305] Market and Regulatory Environment - The FDA announced a final rule on the regulation of Laboratory Developed Tests (LDTs) on April 29, 2024, impacting the regulatory landscape[252] - Inflation did not have a material effect on the company's business during the years ended December 31, 2024, 2023, and 2022, but ongoing inflationary pressures may impact future financial results[307] - The company does not hedge foreign currency exchange risks, which primarily involve operations in the United Kingdom, and currently does not consider these risks significant[311] Segment Performance - The combined segment accounted for 100% of consolidated revenue in 2024, with Clinical Services contributing 84% and Advanced Diagnostics 16% in 2023[264] - The company simplified its operational approach by consolidating its two primary segments into a single segment in Q4 2024[1] Stock and Debt Management - The Company adopted the 2023 Equity Incentive Plan, allowing for the issuance of up to 29.6 million shares of common stock for equity incentives[436] - The Company completed the sale of $201.3 million of 2025 Convertible Senior Notes at a stated interest rate of 1.25%, with net proceeds of approximately $194.5 million after discounts and expenses[426] - The effective interest rate on the 2025 Convertible Notes is 1.96%, which includes the interest and amortization of the debt discount and issuance costs[434] - As of December 31, 2024, the total long-term debt, net, is $340.335 million, compared to $538.198 million in 2023, indicating a significant reduction in long-term debt[412]

4Q 2024 Earnings Results Nasdaq: NEO 1 February 18, 2025 Safe Harbor Statements This presentation has been prepared by NeoGenomics, Inc. ("we," "us," "our," "NeoGenomics" or the "Company") and is made for informational purposes only and does not constitute an offer to sell or a solicitation of an offer to buy securities, nor shall there be any sale of any securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the secur ...